All News

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

Catch up on important continuous glucose monitoring (CGM) news from the month of June.

In case you missed it, this week we had news about mosquito-associated health risks, the link between cannabis and COVID-19, user experience in continuous glucose monitoring, and more.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Through a test-and-treat approach, patients who test positive for HCV RNA with the Xpert HCV test and GeneXpert Xpress System can be connected to care as soon as the same health care visit.

Drug Topics has been on site at McKesson ideaShare this week! Check out this podcast to hear a few of the things we've experienced and what we've learned so far.

Check out these important FDA updates from the month of June 2024.

At McKesson ideaShare 2024, Andrea Sikora discussed artificial intelligence and how it has gradually been integrated into health care systems.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

“Retail pharmacy is central to our future and to our overall customer and patient experience. It enables many other things, but it has to change,” said Walgreens CEO Tim Wentworth.

The first-in-class selective dual PDE3 and PDE4 inhibitor from Verona Pharma is the first inhaled product with a novel mechanism of action approved to treat COPD in over 20 years.

Check out this list of our top 10 most read stories from June 2024.

A study found that cannabis use increased the risk of hospitalization and intensive care unit admission following a COVID-19 diagnosis.

Check out these featured Drug Topics expert interviews from June 2024.

Drug Topics has been on site at McKesson ideaShare this week. Check out this podcast to hear a few of the exciting happenings at this year’s meeting.

The can’t-miss event on July 13 features speakers and CE sessions focused on streamlining pharmacy finances and services.

A study found that having a high level of melanoma knowledge was significantly correlated with having risk factors for the disease, such as skin ultraviolet radiation vulnerability and lighter hair color.

Check out these top featured stories from Drug Topics in June 2024.

In case you missed it, this week we had news about migraine myths, the ongoing bird flu outbreak, improving vaccine hesitancy, and more.

The strongest independent predictors of becoming adherent to dermatology follow-up included younger age and prior outpatient visits.

Check out important updates from the FDA for the week of June 17.

Patrick Alonso, PharmD, CPh, owner and manager of Your Tampa Health Care Advocates, talks about how to build trust with male patients, what health screenings men should be getting, and how pharmacists can help support men’s mental health.

Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.

For Migraine and Headache Awareness Month, Drug Topics spoke with Shivang Joshi, MD, MPH, RPh, FAHS to debunk migraine myths and explore resources to promote migraine awareness and education.

A poster presented at AHS 2024 found that older patients tended to have more vitamin deficiencies compared to younger patients.

Cefepime/enmetazobactam was granted a 5-year exclusivity extension under GAIN Act legislation.

Medication nonadherence can account for up to 50% of treatment failures and over $500 billion in annual health care costs.